Altimmune, Inc. (NASDAQ:ALT) Stock Has Consensus Target Price of $14.33 According to Brokerages

Altimmune, Inc. (NASDAQ:ALT) has been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $14.33.

Several research firms have recently weighed in on ALT. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research report on Monday, September 21st. Evercore restated an “outperform” rating on shares of Altimmune in a report on Wednesday, September 23rd. Wall Street Zen upgraded shares of Altimmune from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its position in Altimmune by 268.7% during the first quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company’s stock valued at $3,221,000 after acquiring an additional 762,223 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Altimmune in the second quarter valued at approximately $2,097,000. Hennion & Walsh Asset Management Inc. grew its position in Altimmune by 156.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 518,198 shares of the company’s stock worth $1,575,000 after acquiring an additional 316,209 shares in the last quarter. Bank of America Corp DE grew its position in Altimmune by 48.6% in the first quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock worth $1,756,000 after acquiring an additional 186,420 shares in the last quarter. Finally, Squarepoint Ops LLC grew its position in Altimmune by 1,016.5% in the second quarter. Squarepoint Ops LLC now owns 202,380 shares of the company’s stock worth $615,000 after acquiring an additional 184,254 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Price Performance

NASDAQ ALT opened at $2.17 on Tuesday. The company has a 50-day moving average price of $2.94 and a two-hundred day moving average price of $2.96. Altimmune has a 52 week low of $2.15 and a 52 week high of $6.44. The stock has a market cap of $422.11 million, a price-to-earnings ratio of -2.78 and a beta of 0.06. The company has a current ratio of 26.78, a quick ratio of 26.78 and a debt-to-equity ratio of 0.07.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. Analysts forecast that Altimmune will post -0.58 EPS for the current year.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for obesity and liver diseases. The company’s research programs are designed to address metabolic and inflammatory conditions with significant unmet medical needs.

Altimmune’s lead product candidate is pemvidutide, an investigational dual GLP-1 and glucagon receptor agonist being evaluated for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease.